EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model

Yue Zhang iD, Huiqin Zhang, Naibo Hu, Liping Yang, Yumei Liu, Liyan Yang, Xifeng Dong, Huaquan Wang iD

Journal of Clinical Laboratory Analysis · 2026

DOI: 10.1002/jcla.70161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2026. Verfasst von Yue Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Bone Marrow Failure Disorders, Hematopoiesis. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune‐mediated bone marrow failure (AA) is characterized by T cell‐mediated destruction of hematopoietic stem and progenitor cells (HSPCs). The JAK–STAT signaling pathway plays a crucial role in regulating immune responses, and JAK inhibitors have shown potential in treating immune‐mediated disorders. This study investigates the effects of MMB, a JAK inhibitor, in a mouse model of immune‐mediated bone marrow failure to evaluate its impact on hematopoiesis and immune cell function.

Methods

In this study, immune‐mediated AA was induced in B6D2F1 female mice through irradiation and lymphocyte infusion. The mice were treated with MMB monotherapy at doses of 6.25 and 12.5 mg/kg for 14 days. Peripheral blood cell counts, bone marrow cell counts, plasma cytokine levels, T lymphocyte subsets, Fas/FasL expression, and hematopoietic stem and progenitor cell (HSPC) levels were analyzed to assess the effects of MMB treatment on immune function and hematopoiesis.

Results

MMB treatment exacerbated the reduction in peripheral blood cell counts in marrow failure mice and decreased bone marrow hematopoietic cell numbers. Concurrently, MMB also reduced cytokine levels. The treatment also led to a significant reduction in CD4 + T cells and Tregs in both the spleen and bone marrow, while the low‐dose MMB group exhibited a decrease in CD8+ T cell count. Additionally, MMB did not significantly improve HSPC levels, and a decrease in the more primitive LSK and LT‐HSC populations was observed. However, later‐stage stem and progenitor cells, such as ST‐HSCs, MPPs, and CMPs, showed an increase in numbers. The treatment also resulted in downregulation of Fas expression on non‐T cells, while FasL expression on lymphocytes increased.

Conclusion

MMB treatment exacerbated peripheral blood cell reduction and impaired bone marrow hematopoiesis in the immune‐mediated AA mouse model. Although MMB modulated T lymphocyte subsets, it did not significantly improve hematopoietic stem and progenitor cell function. These findings highlight the need for further research to explore the potential and limitations of JAK inhibitors like MMB in the treatment of immune‐mediated bone marrow failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsBone Marrow Failure DisordersHematopoiesisBenzamidesPyrimidinesDisease Models, AnimalAnimalsMiceFemaleBlood Cell CountBone MarrowHematopoietic Stem Cells

Stichwörter der Autor:innen

aplastic anemiabone marrow failuremomelotinib

Substanzen

momelotinibJanus Kinase InhibitorsBenzamidesPyrimidines

Autor:innen und Institutionen

  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Hematology, Haihe Hospital, Tianjin University, Tianjin, China.
  • Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin, China.
  • Tianjin Institute of Hematology, Tianjin, China.

ORCID-Profile: Yue Zhang, Huaquan Wang

Zitieren

APA

Zhang, Y., Zhang, H., Hu, N., Yang, L., Liu, Y., Yang, L., Dong, X., & Wang, H. (2026). The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.70161

Vancouver

Zhang Y, Zhang H, Hu N, Yang L, Liu Y, Yang L, et al. The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model. Journal of Clinical Laboratory Analysis. 2026. doi:10.1002/jcla.70161

BibTeX
@article{Zhang2026,
  author = {Zhang, Yue and Zhang, Huiqin and Hu, Naibo and Yang, Liping and Liu, Yumei and Yang, Liyan and Dong, Xifeng and Wang, Huaquan},
  title = {The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2026},
  doi = {10.1002/jcla.70161}
}
Kostenlos starten →